FDA cites Lupin for lax oversight of equipment breakdowns, poor follow up and more
Regulatory NewsJoanne S. Eglovitch
AsiaAudit/inspectionChemistry, Manufacturing and Controls (CMC)ComplianceEthicsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy